Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Please share Science & Enterprise

Off-the-Shelf Stem Cell Company Forms, Gains $72M

Drop of blood

A new enterprise developing packaged blood-forming stem cells as therapies for a range of diseases began operations and raised $72 million in venture funds. . . . → Read More: Off-the-Shelf Stem Cell Company Forms, Gains $72M

Pharma, Biotech Partner on Off-the-Shelf Cell Therapies

Mitochondria illustration

A biotechnology enterprise is teaming with a pharmaceutical company to develop off-the-shelf therapies for malfunctioning mitochondria, energy centers of cells. . . . → Read More: Pharma, Biotech Partner on Off-the-Shelf Cell Therapies

FDA Clears Stem Cell Trial for Multiple Sclerosis

neurons

The Food and Drug Administration has authorized a clinical trial of stem cells extracted and cultured from patients to treat their cases of multiple sclerosis. . . . → Read More: FDA Clears Stem Cell Trial for Multiple Sclerosis

FDA Okays Trial of Donated Stem Cells for Parkinson’s

Neurons

An organization studying stem cell therapies says it received FDA authorization for a clinical trial to test donated stem cells to treat Parkinson’s disease. . . . → Read More: FDA Okays Trial of Donated Stem Cells for Parkinson’s

Trial to Test Direct Crispr Blood Stem Cell Edits

Sickle cells illustration

A clinical trial is set to begin that tests a direct form of gene editing with Crispr to correct inherited malfunctioning genes causing sickle cell disease. . . . → Read More: Trial to Test Direct Crispr Blood Stem Cell Edits

Cell-Based Fish Company Gains $8.25M in Seed Funds

Bluu Bioscience founders

The start-up enterprise Bluu Biosciences is underway creating seafood products from fish stem cells, and raising $US 8.25 million in seed funds. . . . → Read More: Cell-Based Fish Company Gains $8.25M in Seed Funds

Biotech Manufacturer Gains $525M in New Funds

BaseCamp lab

A company providing specialized lab and manufacturing services for cell and gene therapy developers is raising $525 million in its third venture funding round. . . . → Read More: Biotech Manufacturer Gains $525M in New Funds

In-Body Gene Editing Tested as Sickle Cell Treatment

Crispr graphic

Tests with lab mice show the feasibility of editing genes in blood-forming stem cells in bone marrow as a potential treatment for sickle cell disease. . . . → Read More: In-Body Gene Editing Tested as Sickle Cell Treatment

ALS Trial Results Deemed Insufficient for FDA Approval

Neurons illustration

An ALS treatment developer says the Food and Drug Administration advised the company’s clinical trial data would likely not support approval for patient use. . . . → Read More: ALS Trial Results Deemed Insufficient for FDA Approval

Engineered Cell Therapy Company Issues $588M IPO

NASDAQ share price display

A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO. . . . → Read More: Engineered Cell Therapy Company Issues $588M IPO